Dren Bio has generated a broad and diverse pipeline that encompasses multiple clinical and preclinical programs. Both DR-01 and the Targeted Myeloid Engager and Phagocytosis Platform are wholly owned and were developed by leveraging Dren Bio's deep expertise in immunology and protein engineering.
| Program | Therapeutic area | Development stage |
|---|---|---|
| DibotatugDR-01Selective autoreactive cell depletion | Hematologic Malignancies | Phase 2 |
| Autoimmunity | Phase 1 | |
| DR-0202Myeloid engagerTargeted Myeloid Engager and Phagocytosis Platform | Solid Tumors | Phase 1 |
| Multiple undisclosed programsPlatform-derived multispecific antibodies | Oncology, Immunology, Neuroscience | Various stages of development |
| Partnered programs | Oncology | Partnered with Pfizer and Novartis |
| Autoimmunity | Partnered with Sanofi | |
| Acquired programs | Oncology, Autoimmunity | Acquisition of clinical DR-0201 (SAR448501) by Sanofi1 |
1. Press Release: Sanofi completes acquisition of DR-0201 (May 27, 2025)
DR-01, selective autoreactive cell depletion
Phase 2 in LGLL and CTL
DR-01 is a first-in-class antibody therapeutic designed to selectively deplete terminally differentiated cytotoxic cells such as autoreactive CD8 T cells, which are known to play a pathogenic role in various hematological and autoimmune diseases.
DR-01 is currently being evaluated in large granular lymphocytic leukemia (LGLL) and cytotoxic lymphoma (CTL) patients and is expanding into various autoimmune indications.
Second platform program
First-in-human study initiated June 2025
DR-0202 is a first-in-class bispecific antibody that harnesses myeloid cells to selectively deplete cancer cells by targeting a cell surface receptor that is highly expressed in various solid tumors.
By leveraging myeloid cells to deplete tumor cells and subsequently cross-present antigens, DR-0202 primes the adaptive immune system to potentially elicit deep and durable responses.
Platform-derived
Preclinical
Dren Bio's versatile platform has yielded a deep pipeline of preclinical programs across various therapeutic areas including oncology, immunology and neurology.